"Efficacy Respiratory Physiotherapy On Allergic Bronchopulmonary Aspergillosis. A Case Report"

Background: Allergic bronchopulmonary aspergillosis (ABPA) is a disease characterized by reversible airway obstruction. The clinical symptomatology involves recurrent episodes predominantly in subjects with asthma, those with cystic fibrosis, and subjects with bronchiectasis. Methods: A respiratory...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of physiotherapy 2022-03, Vol.9 (1)
Hauptverfasser: Milá, Zacarías Sánchez, Saornil, Jorge Velázquez, Chekroun, Angélica Campón, Jiménez, Elena Sánchez, Sánchez, Sonia Gómez, Jiménez, Ana Martín
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Allergic bronchopulmonary aspergillosis (ABPA) is a disease characterized by reversible airway obstruction. The clinical symptomatology involves recurrent episodes predominantly in subjects with asthma, those with cystic fibrosis, and subjects with bronchiectasis. Methods: A respiratory physiotherapy treatment plan of home training with The Acapella DH® provides the oscillatory positive expiratory pressure (OPEP) and POWERbreathe Plus® for two weeks, five days a week, twice a day (10 minutes in the morning and another 10 minutes in the afternoon) and to analyze the effectiveness of respiratory therapy using spirometry, as a treatment for a clinical case suffering from allergic bronchopulmonary aspergillosis, bronchial asthma, and bronchiectasis. Results: The first spirometric assessment carried out on week zero revealed that after the home treatment plan in week one and week two assessments, a significant increase in all spirometric lung function values was assessed with % change, such as Vital Capacity (VC), resulting in week 1 (0.80%) week 2 (1.09%), Tidal Volume (VT) resulting in week 1 (0.91%) week 2 (1.04%), Expiratory Reserve Volume (ERV) resulting in week 1 (1.14%) week 2 (1.24%), Inspiratory Reserve Volume (IRV) resulting in week 1 (0.66%) week 2 (1.04%) and Inspiratory Capacity (IC) resulting in week 1 (0.69%) week 2 (0.71%), together with decreasing respiratory times; inspiratory time (Ti) resulting in week 1 (-0.31%) week 2 (-0.38%), expiratory time (Te) and total inspiratory and expiratory time (Tt) resulting in week 1 (-0.24%) week 2 (-0.31%). Conclusions: A home pulmonary treatment plan with OPEP and POWERbreathe Plus® shows a clear improvement in lung function in subjects with ABPA, bronchiectasis, and asthma, thus improving quality of life.
ISSN:2349-5987
2348-8336
DOI:10.15621/ijphy/2022/v9i1/1148